Azopt
FDA Approves Retinal Implant for Rare Genetic Eye Disease »
"The U.S. Food and Drug Administration today approved the Argus II Retinal Prosthesis System, the first implanted device to treat adult patients with advanced retinitis pigmentosa (RP). The device, which includes a small video camera, transmitter "...
Read the FDA Approves Retinal Implant for Rare Genetic Eye Disease article »
Azopt
INDICATIONS
AZOPT® (brinzolamide ophthalmic suspension) (brinzolamide ophthalmic suspension) 1% is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
DOSAGE AND ADMINISTRATION
The recommended dose is one drop of AZOPT® (brinzolamide ophthalmic suspension) 1% in the affected eye(s) three times daily. If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten (10) minutes apart.
HOW SUPPLIED
Dosage Forms And Strengths
Solution containing 10 mg/mL brinzolamide.
AZOPT® (brinzolamide ophthalmic suspension) 1% is supplied in plastic DROP-TAINER® dispensers with a controlled dispensing-tip as follows:
| 5 mL | NDC 0065-0275-05 |
| 10 mL | NDC 0065-0275-10 |
| 15 mL | NDC 0065-0275-15 |
Storage and Handling
Store AZOPT® (brinzolamide ophthalmic suspension) 1% at 4-30°C (39-86°F). Shake well before use.
Alcon Laboratories, Inc. Fort Worth, Texas 76134 USA. Revised: 8/2010
Last reviewed on RxList: 4/28/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Azopt Information
Azopt - User Reviews
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
WebMD Daily
Get breaking medical news.






